NeuroBo Pharmaceuticals (NASDAQ:NRBO) said a safety review committee has recommended that a two-part Phase 2a study of its drug candidate DA-1241 for the treatment of MASH continue without any modifications.
The company is testing DA-1241 for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH.
A full data readout from the Phase 2a trial is expected in the second half of the year. The primary endpoint for both parts of the study is the change from baseline in alanine transaminase, or ALT, levels at week 16, according to the company.